Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Peter V who wrote (5119)	5/26/1999 11:42:00 PM
From: spunky71	Read Replies (1) \| Respond to of 5736

Peter V, I agree with thinking about the future, and if I may take a stab at it, here is my two cents worth. There are 14-15mm heelsticks done in the US annually. SPRX, not a very good product, according to the industry, estimates the worldwide bilirubin market at $180mm annually. About 1/3 of that is US, and I believe they charge somewhere around $5 for their test, which is not very helpful, so CCSI's market according to those figures could be $120mm in the US. The majority, around 70% of the sticks are done in NICU's ,say 9-10mm, and that represents about 600 some odd hospitals. If CCSI is able to join with someone the penetration should occur more quickly, if they don't I would guess it will take them 2 years to penetrate that market alone. By themselves I have given them a 30% penetration in year 2, or say 3.0mm lensettes @$10 per. There will be revenues from sales of machines also, and I would guess $1500+ gross profit, but the bet is that hospitals, pediatricians, and home health care will ramp up also in that time frame, and my base guess could prove to be very conservative, and because these are recurring revenues I attach a higher multiple, say 25x. As they also have foreign approvals, there is a possibility of teaming up with regional distributors there, and that could be additive. Now, we really jump into the sublime. Giving them no credence for what they already have, I am sure no one will give them anything for other markets either, but my guess is dentistry is going to be the surprise. No FDA, a few key firms in the arena, over 60mm applications a year, for bonding and caps, and there is some potentail add ons to my guesses from above. The past is past, the future is what I bet on, and I am betting that we will see them make some major inroads into both of these markets in the next 2 years, and I also have 3.3mm shares as non-believers, with a limited float. For my money a decent shot at making some dough.

To: Peter V who wrote (5119)	5/26/1999 11:59:00 PM
From: Peter Goss	Read Replies (1) \| Respond to of 5736

Peter - All the long "geniuses" haven't said a word about the quick trip to low $9 range this morning. They focus on Darby's television side show and live promises instead of just ones listed in a PR. Surely if she said it on TV it must be true <g>. This company could not make the product saleable in the market it was intended for (cosmetics) and now it is going to be bilirubin and dentistry. Now those markets are where they have some real expertise. All I have to do to be comfortable with my short is to measure how much idiocy appears on the YHOO and SI boards whenever something "good" happens. The morons on parade were marching in lockstep to their brokers to put the dreaded squeeze on the shorts. I'll borrow some more each time they roar. I'm patient; they are nervous and angry. good trading, Peter G.